Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo.
Combining inhaled corticosteroids (ICSs), long-acting β2 -adrenoceptor (β2 -AR) agonists (LABAs), and long-acting muscarinic antagonists (LAMAs) is recommended to treat severe forms of asthma and chronic obstructive pulmonary disease (COPD). Clinical benefits have been demonstrated for ICS/LABA/LAMA combinations. This study characterized the interaction between the ICS beclomethasone dipropionate (BDP), the LABA formoterol fumarate (FF), and the LAMA glycopyrronium bromide (GB) in human airways. Human passively sensitized airways and bronchi from COPD donors were stimulated by histamine or carbachol, respectively. Tissues were incubated overnight with BDP, and then treated with FF, and GB, alone or in triple combination. The interaction was assessed by using Bliss Independence and Unified Theory theorems. BDP/FF/GB combination synergistically relaxed medium bronchi (overall delta effect vs. expected additive effect +47.61%±2.69%; P<0.001) and small airways (overall delta effect vs. expected additive effect +26.90%±6.43%; P<0.05). BDP/FF/GB combination at 100:6:12.5 combination-ratio was a balanced drug mixture leading to very strong synergistic effect on relaxation of medium bronchi (Combination Index: from 0.042 to 0.96), and middle to very strong synergy in small airways (Combination Index: from 0.018 to 0.310). The synergy was related with the activation of intracellular glucocorticoid receptors and Gsα subunit G-protein of β2 -AR, leading to the modulation of cyclic adenosine monophosphate -dependent protein kinase A pathway. Triple BDP/FF/GB combination induces synergistic bronchorelaxant effect in medium and small human airways, at least in ex vivo experiments. Further research is needed to confirm these findings in clinical studies in patients with asthma or COPD.